Debt-to-equity of Acurx Pharmaceuticals, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Acurx Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Acurx Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 107%, a 41% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Acurx Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 107% +31% +41% 30 Sep 2025
Q2 2025 127% +58% +83% 30 Jun 2025
Q1 2025 135% +76% +127% 31 Mar 2025
Q4 2024 101% +45% +79% 31 Dec 2024
Q3 2024 75% +30% +65% 30 Sep 2024
Q2 2024 70% +40% +138% 30 Jun 2024
Q1 2024 60% +41% +221% 31 Mar 2024
Q4 2023 56% +45% +374% 31 Dec 2023
Q3 2023 46% +38% +506% 30 Sep 2023
Q2 2023 29% +23% +405% 30 Jun 2023
Q1 2023 19% +11% +139% 31 Mar 2023
Q4 2022 12% 31 Dec 2022
Q3 2022 8% 30 Sep 2022
Q2 2022 6% 30 Jun 2022
Q1 2022 8% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.